La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Boliden a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Boliden..

Boliden (OTC:BLIDF) Azioni, Catena delle Opzioni

Boliden AB operates six mining areas and five smelters in Sweden, Norway, Finland, and Ireland. The company processes zinc, copper, gold, silver and other metals and is engaged in exploration, mining, smelting, and metals recycling. The company has two operating segments: business area smelters and business area mines. The business area mines division comprises six mining areas: Aitik, the Boliden Area, and Garpenberg in Sweden; Kylylahti and Kevitsa in Finland; and the Tara mine in Ireland. It includes both underground mines and open-pit mines. The company generates maximum revenue from Business area Smelters segment.

Boliden AB

DA Davidson analyst Tom White maintains Zillow Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZG#NASDAQ">ZG</a>) with a Buy and raises the price target from $71 to $75.

News

Price Target

Analyst Ratings

DA Davidson Maintains Buy on Zillow Gr, Raises Price Target to $75

WIIM

FBIN

Fortune Brands shares are trading lower after the company reported worse-than-expected Q3 revenue results and cut its FY24 guidance. Multiple firms lowered their respective price targets on the stock.

Bernstein analyst Stacy Rasgon maintains Qualcomm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) with a Outperform and raises the price target from $200 to $215.

QCOM

Bernstein Maintains Outperform on Qualcomm, Raises Price Target to $215

DA Davidson analyst Rudy Kessinger maintains Rapid7 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPD#NASDAQ">RPD</a>) with a Neutral and raises the price target from $35 to $39.

DA Davidson Maintains Neutral on Rapid7, Raises Price Target to $39

DBGI

Digital Brands Group Repays All Convertible Debt Securities, Extinguishing Obligations Under Securities Purchase Agreements; Announces Debt-Free Status In Press Release

Craig-Hallum analyst Greg Palm maintains Faro Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FARO#NASDAQ">FARO</a>) with a Buy and raises the price target from $25 to $30.

FARO

Craig-Hallum Maintains Buy on Faro Technologies, Raises Price Target to $30

Dutch Bros Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>) stock hit a new 52-week high on Thursday after the company reported better-than-expected financial results and raised its full-year guidance above estimates. Here&#8217;s what <a href="https://www.benzinga.com/news/earnings/24/11/41791482/dutch-bros-stock-perks-up-after-solid-q3-earnings-report-details">you need to know</a>. 
The Details: Dutch Bros stock soared about 15% after the market closed on Wednesday following the release of the company&#8217;s third-quarter earnings, which included adjusted earnings per share of 16 cents, beating analyst estimates of 12 cents.
In addition, the company reported sales of $338.21 million, beating analyst estimates of $325.14 million. Dutch Bros&#8217; top-line results were up about 28% year-over-year. The company also reported company-operated shop revenues of $308.3 million, representing a 30% year-over-year increase.
The company reported adjusted EBITDA of $63.8 million, compared to $53 million in the same period last year. Dutch Bros also reported adjusted selling, general and administrative expenses totaling $57.5 million.
Throughout the third quarter, Dutch Bros opened 38 new stores across 11 states with 33 of those stores being company-operated.
&#8220;We believe our refined real estate strategy is working, as we are seeing strong new shop productivity as we have shifted our development focus and elevated our site selection process,&#8221; said Dutch Bros CEO Christine Barone.
&#8220;We continue to demonstrate remarkable consistency in our shop opening cadence with 38 shop openings in the&nbsp;third quarter. We are making major investments in our development and construction teams and our 2025 pipeline is strong, positioning us to accelerate new shop growth.&#8221;
Dutch Bros also raised its guidance for the full year above estimates. The company now expects revenue between $1.25 billion and $1.26 billion, versus analyst estimates of $1.23 billion. Dutch Bros previously guided for revenue of $1.21 billion to $1.23 billion.
Additionally, Dutch Bros said it expects adjusted EBITDA of $215 million to $220 million, up from its prior outlook of $200 million to $210 million.
See Also:<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41792455/jpmorgan-bank-of-america-and-wells-fargo-shares-surged-wednesday-heres-why"> JPMorgan, Bank Of America And Wells Fargo Shares Surged Wednesday: Here&#8217;s Why</a>
Analyst Changes: Following the earnings report, multiple analysts issued price target adjustments.
<ul>
<li>TD Cowen analyst Andrew Charles maintained a Buy rating on Dutch Bros and raised the price target from&nbsp;$47&nbsp;to&nbsp;$53.</li>
<li>Wedbush analyst Nick Setyan maintained an Outperform rating on Dutch Bros and raised the price target from $45 to $55.</li>
<li>UBS analyst Dennis Geiger maintained a Buy rating on Dutch Bros and raised the price target from&nbsp;$39&nbsp;to&nbsp;$44.</li>
<li>Baird analyst David Tarantino maintained a Neutral rating on Dutch Bros and raised the price target from $37 to $46.</li>
<li>JPMorgan analyst John Ivankoe maintained an Overweight rating and raised the price target from $44 to $48.</li>
</ul>
BROS Price Action: At the time of writing, Dutch Bros stock was up 32.7% at $46.38, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Courtesy of Dutch Bros Inc.

Guidance

Movers

BROS

Dutch Bros Stock Hits 52-Week Highs: What's Going On?

Argus Research analyst John Staszak maintains Restaurant Brands Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QSR#NYSE">QSR</a>) with a Buy and lowers the price target from $85 to $80.

Argus Research Maintains Buy on Restaurant Brands Intl, Lowers Price Target to $80

DA Davidson analyst Rudy Kessinger maintains Fastly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSLY#NYSE">FSLY</a>) with a Neutral and raises the price target from $5.5 to $7.5.

FSLY

DA Davidson Maintains Neutral on Fastly, Raises Price Target to $7.5

On Thursday, Emergent BioSolutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) stock is trading higher on mixed third-quarter earnings and a new mpox trial in Africa.
The company reported third-quarter sales of $293.8 million, up 9% year over year, with the management guidance of $265&nbsp;million–$315 million, and missing the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $297.5 million</a>.
The company reported an adjusted EPS of $1.37, a turnaround from a loss of $1.09 a year ago,&nbsp;beating <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41786475/emergent-biosolutions-reports-third-quarter-2024-financial-results" rel="noreferrer noopener">the consensus of $0.14</a>.
Revenues from Narcan&nbsp;(naloxone HCl) Nasal Spray decreased 33% to $95.3 million, primarily driven by the discontinuation of prescription Narcan&nbsp;due to the launch of over-the-counter Narcan&nbsp;in the third quarter of 2023 and lower Canadian retail sales, partially offset by higher sales of OTC Narcan.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41026819/emergent-biosolutions-confirms-orders-worth-400m-related-to-smallpox-mpox-vaccines" rel="noreferrer noopener">Emergent BioSolutions Confirms Orders Worth $400M Related To Smallpox, Mpox Vaccines</a>
Revenues from Anthrax MCM fell 65% to $11.4 million, and Smallpox MCM sales jumped more than fivefold to $132.7 million.
Guidance: Emergent BioSolutions updated its 2024 revenue guidance from $1.05 billion &#8211; $1.125 billion to $1.065 billion &#8211; $1.125 billion, compared to the consensus of $1.123 billion.
The updated guidance includes commercial product sales of $420&nbsp;million &#8211;&nbsp;$430 million compared to <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40226161/vaccine-maker-emergent-biosolutions-expects-deeper-losses-in-2024-stock-sinks" rel="noreferrer noopener">prior guidance of </a>$450 million – $480 million.
MCM Product sales outlook of $510&nbsp;million &#8211; $550 million, compared to $455&nbsp;million – $490 million expected earlier.
Services segment sales are expected to be $105&nbsp;million &#8211; $110 million, lower than the prior range of $120&nbsp;million – $130 million.
The company expects a 2024 net loss of $203 million &#8211; $183 million, compared to the previous loss range of $314 million – $274 million, and an adjusted EBITDA of $180 million &#8211; $200 million compared to previous forecast of $140 million &#8211; $180 million.
Concurrently, Emergent BioSolutions announced that brincidofovir (brand name Tembexa for smallpox treatment) will be included in a trial conducted and sponsored by PANTHER, under the leadership of the Africa Centres for <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41789320/emergent-biosolutions-supports-new-clinical-trial-evaluating-the-safety-and-efficacy-of-brincidofo" rel="noreferrer noopener">Disease Control and Prevention</a>.
The study will evaluate the safety and efficacy of brincidofovir in treating mpox virus. The trial is scheduled to begin in the coming weeks in the Democratic Republic of Congo and neighboring countries.
Price Action: EBS stock is up 28.3% at $11.80 at last check Thursday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41816035/ralph-lauren-soars-as-q2-results-outpace-expectations-ceo-eyes-holiday-season-with-raised-revenue-g" target="_blank" rel="noreferrer noopener">Ralph Lauren Soars As Q2 Results Outpace Expectations—CEO Eyes Holiday Season With Raised Revenue Goals</a></li>
</ul>

Biotech

Earnings

Equities

Health Care

Trading Ideas

General

Mpox Vaccine Player Emergent BioSolutions Stock Jumps On Upbeat Annual Forecast, Expects Smaller Losses In 2024

DA Davidson analyst Kurt Yinger maintains TopBuild (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLD#NYSE">BLD</a>) with a Buy and lowers the price target from $460 to $450.

DA Davidson Maintains Buy on TopBuild, Lowers Price Target to $450

Argus Research analyst Joseph Bonner maintains Electronic Arts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>) with a Buy and raises the price target from $161 to $183.

Argus Research Maintains Buy on Electronic Arts, Raises Price Target to $183

Craig-Hallum analyst Richard Shannon maintains IonQ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) with a Buy and raises the price target from $15 to $22.

IONQ

Craig-Hallum Maintains Buy on IonQ, Raises Price Target to $22

Moleculin Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>) is set to give its latest quarterly earnings report on Friday, 2024-11-08. Here's what investors need to know before the announcement.
Analysts estimate that Moleculin Biotech will report an earnings per share (EPS) of $-2.44. 
Investors in Moleculin Biotech are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Overview of Past Earnings</h3>
In the previous earnings release, the company beat EPS by $0.61, leading to a 10.8% drop in the share price the following trading session.
Here's a look at Moleculin Biotech's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-2.31</td>
<td>-3.53</td>
<td>-3.05</td>
<td>-3.60</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.70</td>
<td>-2.02</td>
<td>-5.09</td>
<td>-2.85</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-11.0%</td>
<td>-0.0%</td>
<td>-14.000000000000002%</td>
<td>-5.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731006266_0.png" alt="eps graph" />
<h3>Market Performance of Moleculin Biotech's Stock</h3>
Shares of Moleculin Biotech were trading at $2.36 as of November 06. Over the last 52-week period, shares are down 71.6%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/MBRX/earnings">To track all earnings releases for Moleculin Biotech visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MBRX

Insights Ahead: Moleculin Biotech's Quarterly Earnings

ANI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIP#NASDAQ">ANIP</a>) is preparing to release its quarterly earnings on Friday, 2024-11-08. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect ANI Pharmaceuticals to report an earnings per share (EPS) of $1.07.
Anticipation surrounds ANI Pharmaceuticals's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Earnings History Snapshot</h3>
Last quarter the company beat EPS by $0.08, which was followed by a 9.92% drop in the share price the next day.
Here's a look at ANI Pharmaceuticals's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.94</td>
<td>0.99</td>
<td>0.85</td>
<td>0.84</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.02</td>
<td>1.21</td>
<td>1</td>
<td>1.27</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-10.0%</td>
<td>3.0%</td>
<td>-1.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731006258_0.png" alt="eps graph" />
<h3>ANI Pharmaceuticals Share Price Analysis</h3>
Shares of ANI Pharmaceuticals were trading at $58.4 as of November 06. Over the last 52-week period, shares are up 12.64%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Observations about ANI Pharmaceuticals</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on ANI Pharmaceuticals.
Analysts have given ANI Pharmaceuticals a total of 5 ratings, with the consensus rating being Neutral. The average one-year price target is $73.4, indicating a potential 25.68% upside.
<h3>Comparing Ratings Among Industry Peers</h3>
The following analysis focuses on the analyst ratings and average 1-year price targets of Tilray Brands, Collegium Pharmaceutical and Evolus, three prominent industry players, providing insights into their relative performance expectations and market positioning.
<ul>
<li>For Tilray Brands, analysts project an Neutral trajectory, with an average 1-year price target of $1.75, indicating a potential 97.0% downside.</li>
<li>The consensus outlook from analysts is an Buy trajectory for Collegium Pharmaceutical, with an average 1-year price target of $41.5, indicating a potential 28.94% downside.</li>
<li>The consensus outlook from analysts is an Buy trajectory for Evolus, with an average 1-year price target of $24.6, indicating a potential 57.88% downside.</li>
</ul>
<h3>Snapshot: Peer Analysis</h3>
Within the peer analysis summary, vital metrics for Tilray Brands, Collegium Pharmaceutical and Evolus are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANI Pharmaceuticals</td>
<td>Neutral</td>
<td>18.44%</td>
<td>$80.34M</td>
<td>-0.59%</td>
</tr>
<tr>
<td>Tilray Brands</td>
<td>Neutral</td>
<td>13.05%</td>
<td>$59.71M</td>
<td>-1.13%</td>
</tr>
<tr>
<td>Collegium Pharmaceutical</td>
<td>Buy</td>
<td>7.18%</td>
<td>$90.81M</td>
<td>8.94%</td>
</tr>
<tr>
<td>Evolus</td>
<td>Buy</td>
<td>35.59%</td>
<td>$47.83M</td>
<td>-60.12%</td>
</tr>
</tbody>
</table>

Key Takeaway:
ANI Pharmaceuticals ranks in the middle for consensus rating among its peers. It is at the bottom for revenue growth. In terms of gross profit, it is at the top among its peers. However, for return on equity, it is at the bottom compared to its peers.
<h3>Discovering ANI Pharmaceuticals: A Closer Look</h3>
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
<h3>A Deep Dive into ANI Pharmaceuticals's Financials</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: ANI Pharmaceuticals's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 18.44%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -1.95%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): ANI Pharmaceuticals's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -0.59%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): ANI Pharmaceuticals's ROA excels beyond industry benchmarks, reaching -0.29%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.63.
<a href="https://www.benzinga.com/quote/ANIP/earnings">To track all earnings releases for ANI Pharmaceuticals visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ANIP

A Peek at ANI Pharmaceuticals's Future Earnings

InflaRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IFRX#NASDAQ">IFRX</a>) is gearing up to announce its quarterly earnings on Friday, 2024-11-08. Here's a quick overview of what investors should know before the release.
Analysts are estimating that InflaRx will report an earnings per share (EPS) of $-0.28.
InflaRx bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Earnings History Snapshot</h3>
Last quarter the company missed EPS by $0.05, which was followed by a 2.99% increase in the share price the next day.
Here's a look at InflaRx's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.21</td>
<td>-0.24</td>
<td>-0.2</td>
<td>-0.25</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.26</td>
<td>-0.18</td>
<td>-0.3</td>
<td>-0.14</td>
</tr>
<tr>
<td>Price Change %</td>
<td>3.0%</td>
<td>0.0%</td>
<td>-3.0%</td>
<td>-14.000000000000002%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731006244_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of InflaRx were trading at $1.53 as of November 06. Over the last 52-week period, shares are up 17.97%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<a href="https://www.benzinga.com/quote/IFRX/earnings">To track all earnings releases for InflaRx visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

IFRX

Earnings Preview: InflaRx

Craig-Hallum analyst Greg Palm maintains Kornit Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRNT#NASDAQ">KRNT</a>) with a Buy and raises the price target from $27 to $33.

KRNT

Craig-Hallum Maintains Buy on Kornit Digital, Raises Price Target to $33

Delcath Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) is set to give its latest quarterly earnings report on Friday, 2024-11-08. Here's what investors need to know before the announcement.
Analysts estimate that Delcath Systems will report an earnings per share (EPS) of $-0.22. 
The market awaits Delcath Systems's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Overview of Past Earnings</h3>
During the last quarter, the company reported an EPS missed by $0.12, leading to a 4.93% drop in the share price on the subsequent day.
Here's a look at Delcath Systems's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.36</td>
<td>-0.47</td>
<td>-0.51</td>
<td>-0.52</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.48</td>
<td>-0.45</td>
<td>-0.48</td>
<td>-1.14</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-5.0%</td>
<td>2.0%</td>
<td>10.0%</td>
<td>-24.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731006227_0.png" alt="eps graph" />
<h3>Market Performance of Delcath Systems's Stock</h3>
Shares of Delcath Systems were trading at $10.94 as of November 06. Over the last 52-week period, shares are up 274.92%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Insights on Delcath Systems</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Delcath Systems.
The consensus rating for Delcath Systems is Buy, derived from 2 analyst ratings. An average one-year price target of $21.5 implies a potential 96.53% upside.
<h3>Comparing Ratings Among Industry Peers</h3>
This comparison focuses on the analyst ratings and average 1-year price targets of Pulmonx, AngioDynamics and Zynex, three major players in the industry, shedding light on their relative performance expectations and market positioning.
<ul>
<li>The consensus outlook from analysts is an Buy trajectory for Pulmonx, with an average 1-year price target of $16.0, indicating a potential 46.25% upside.</li>
<li>Analysts currently favor an Buy trajectory for AngioDynamics, with an average 1-year price target of $13.33, suggesting a potential 21.85% upside.</li>
<li>Zynex is maintaining an Buy status according to analysts, with an average 1-year price target of $14.67, indicating a potential 34.1% upside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
The peer analysis summary provides a snapshot of key metrics for Pulmonx, AngioDynamics and Zynex, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Delcath Systems</td>
<td>Buy</td>
<td>1468.89%</td>
<td>$6.25M</td>
<td>-146.09%</td>
</tr>
<tr>
<td>Pulmonx</td>
<td>Buy</td>
<td>15.39%</td>
<td>$15.03M</td>
<td>-14.50%</td>
</tr>
<tr>
<td>AngioDynamics</td>
<td>Buy</td>
<td>-14.22%</td>
<td>$36.72M</td>
<td>-6.36%</td>
</tr>
<tr>
<td>Zynex</td>
<td>Buy</td>
<td>0.10%</td>
<td>$39.79M</td>
<td>6.95%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Delcath Systems ranks first in revenue growth among its peers. It has the lowest gross profit margin. Delcath Systems has the lowest return on equity.
<h3>Delving into Delcath Systems's Background</h3>
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
<h3>Breaking Down Delcath Systems's Financial Performance</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Over the 3 months period, Delcath Systems showcased positive performance, achieving a revenue growth rate of 1468.89% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Delcath Systems's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -176.94%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Delcath Systems's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -146.09%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -39.25%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Delcath Systems's debt-to-equity ratio is below the industry average. With a ratio of 1.33, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<a href="https://www.benzinga.com/quote/DCTH/earnings">To track all earnings releases for Delcath Systems visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DCTH

Uncovering Potential: Delcath Systems's Earnings Preview

DA Davidson analyst Wyatt Swanson maintains Duolingo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NASDAQ">DUOL</a>) with a Buy and raises the price target from $250 to $350.

DUOL

DA Davidson Maintains Buy on Duolingo, Raises Price Target to $350

Over the past 24 hours, Mantle's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">MNT</a>) price has risen 14.54% to $0.68. This continues its positive trend over the past week where it has experienced a 12.0% gain, moving from $0.60 to its current price. As it stands right now, the coin's all-time high is $1.54. 
The chart below compares the price movement and volatility for Mantle over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1731006220_0.png" alt="price_chart" />
Mantle's trading volume has climbed 85.0% over the past week, moving in tandem, directionally, with the overall circulating supply of the coin, which has increased 0.35%. This brings the circulating supply to 3.37 billion, which makes up an estimated 54.14% of its max supply of 6.22 billion. According to our data, the current market cap ranking for MNT is #48 at $2.28 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1731006221_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Comments

Boliden

Boliden (BLIDF) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO